Q-omics provides the consensus-scored STEAP3 profile across patient tissues and cancer cell-line models. STEAP3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STEAP3 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, STEAP3 protein abundance shows 31,357 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UVM, BLCA, and CCRCC as cancer lineages where STEAP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STEAP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STEAP3 survival associations across molecular data types. STEAP3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STEAP3 RNA expression–survival associations across cancer types. High STEAP3 expression shows unfavorable associations in UVM, ACC, KIRP, KIRC, LGG and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STEAP3 RNA expression.
This table summarizes STEAP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STEAP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STEAP3 shows lower tumor expression in LIHC and higher tumor expression in BLCA, KIRC, KIRP, LUAD and THCA. The BLCA box plot shows higher STEAP3 RNA expression in tumor versus normal tissue (log2 FC = +1.899, t-test p < 0.001).
This table shows molecular features associated with STEAP3 in patient tissues and cancer cell lines. In patient samples, STEAP3 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STEAP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
